• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Traws Pharma Announces Management Updates

    3/28/25 4:30:00 PM ET
    $IKNA
    $IOVA
    $TRAW
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IKNA alert in real time by email
    • Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member
    • Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO

    NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assume the role of Interim CEO. In addition to his new responsibilities, Dr. Dukes will continue to serve as Traws' Chairman.

    Dr. Dukes has held leadership roles in public and private biopharmaceutical companies, leveraging vast experience in corporate, strategic and product development. Dr. Cautreels will continue in his role as a member of the Traws Board of Directors and transition to a consulting role as special advisor to the Board for the next year.

    "On behalf of the Board of Directors, I want to express my sincerest appreciation to Werner for his unwavering commitment and dedicated service. Under his leadership, the Company completed the merger with Trawsfynydd to form Traws Pharma, advancing two exciting clinical-stage antiviral candidates for bird flu and COVID," said Dr. Dukes of Traws. "I believe that Traws' novel antiviral programs have the potential to substantially improve the care of people with influenza and COVID. We look forward to reviewing the Company's pipeline progress in our Investor Update call on March 31, 2025."

    "I am grateful to the employees, advisors, investors and collaborators who have supported Traws' development and progress since the merger, just one year ago. It has been a privilege to work with such an impressive management team, and advance our bird flu and COVID programs, while garnering the support of important institutional investors," commented Dr. Cautreels. "I look forward to continuing to support Traws in my new role, as the Company takes the next steps in the development of its portfolio of oral small molecule antivirals."

    Register here for the Investor Call on Monday, March 31, 2025 at 10:00 AM ET.

    About Iain D. Dukes, D Phil

    Dr. Dukes is biopharmaceutical professional with substantial experience in senior leadership roles in venture capital, business development and licensing, as well as drug discovery and development. He is a Venture Partner of OrbiMed Advisors, LLC. Previously, Dr. Dukes served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Before joining Merck, Dr. Dukes held senior leadership roles in Business Development and Research and Development at Amgen, GlaxoSmithkline, and Glaxo Wellcome.

    Dr. Dukes has served on the board of numerous public and private biopharma organizations. He is currently the Chairman of the board of directors of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and Executive Chairman of Angiex Inc. He also serves as a director or founding executive on other public and private boards including Ikena Oncology (NASDAQ:IKNA), ENYO Pharma SA, Kartos Therapeutics, Inc., NeRRe Therapeutics, Rathlin Therapeutics Limited, and Telios Pharma, Inc. Dr. Dukes holds an MA in Jurisprudence and D Phil from the University of Oxford, an MSc in Cardiovascular Studies from the University of Leeds, and a BSc in Pharmacology from the University of Bath.

    About Werner Cautreels

    Dr. Werner Cautreels is a highly accomplished biopharmaceutical executive who brings a deep understanding of research and development, as well as clinical and regulatory strategy, across a range of therapeutic areas. Dr. Cautreels was previously President and CEO of Selecta Biosciences. Prior to Selecta Biosciences, Dr. Cautreels held senior leadership roles at international biopharmaceutical organizations around the world including Solvay Pharmaceuticals (as CEO, acquired by Abbott Laboratories), Sanofi, Sterling Winthrop and Nycomed-Amersham.

    Dr. Cautreels has served as a member of the audit committee and board for biopharmaceutical companies including Innogenetics NV, Arqule Inc., and Galapagos NV. Dr. Cautreels currently serves on the board of directors of Third Pole Therapeutics. Dr. Cautreels also serves as CEO of Cristal Therapeutics and Non-Executive Chairman of MRM Health NV. Dr. Cautreels has a PhD in chemistry from the University of Antwerp, Belgium, and completed the Advanced Management Program at Harvard Business School.

    About Traws Pharma, Inc.

    Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. We are advancing novel investigational antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health. Our product candidates are intended to be safe, with simple dosing regimens. We strive to utilize accelerated clinical trial strategies with a commitment to patients who are especially vulnerable.

    The Company's two antiviral programs are investigational oral small molecules targeting bird flu and seasonal influenza, and COVID-19. Tivoxavir marboxil is in development as a single dose treatment for bird flu and seasonal influenza, targeting the influenza cap-dependent endonuclease (CEN). Ratutrelvir is in development as a COVID treatment, targeting the Main protease (Mpro or 3CL protease), without the need for co-administration of ritonavir.

    For more information, please visit www.trawspharma.com and follow us on LinkedIn.

    Forward-Looking Statements

    Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, benefits, effectiveness, safety, and the clinical and regulatory plans for tivoxavir marboxil and ratutrelvir and the timing of the filing of the Company's Annual Report on Form 10-K. The Company has attempted to identify forward-looking statements by terminology including "believes", "estimates", "anticipates", "expects", "plans", "intends", "may", "could", "might", "will", "should", "preliminary", "encouraging", "approximately" or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including the success and timing of Traws' clinical trials, collaborations, market conditions, regulatory requirements and pathways for approval, the extent of the spread and threat of the bird flu, the ongoing need for improved therapy to reduce the frequency of clinical rebound and the concomitant risk for long COVID, and those discussed under the heading "Risk Factors" in Traws' filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.

    Traws Pharma Contact:

    Nora Brennan

    Traws Pharma, Inc.

    [email protected]

    www.trawspharma.com

    Investor Contact:

    Bruce Mackle

    LifeSci Advisors, LLC

    646-889-1200

    [email protected]



    Primary Logo

    Get the next $IKNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IKNA
    $IOVA
    $TRAW

    CompanyDatePrice TargetRatingAnalyst
    Iovance Biotherapeutics Inc.
    $IOVA
    5/16/2025$2.00Buy → Neutral
    UBS
    Iovance Biotherapeutics Inc.
    $IOVA
    5/12/2025Buy → Hold
    Truist
    Iovance Biotherapeutics Inc.
    $IOVA
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    Iovance Biotherapeutics Inc.
    $IOVA
    10/24/2024$17.00Buy
    UBS
    Iovance Biotherapeutics Inc.
    $IOVA
    7/29/2024$19.00 → $10.00Overweight → Neutral
    Piper Sandler
    Ikena Oncology Inc.
    $IKNA
    5/29/2024$8.00 → $2.00Outperform → Neutral
    Wedbush
    Iovance Biotherapeutics Inc.
    $IOVA
    11/20/2023$12.00Buy
    Goldman
    Ikena Oncology Inc.
    $IKNA
    9/22/2023$11.00Outperform
    Wedbush
    More analyst ratings

    $IKNA
    $IOVA
    $TRAW
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iovance Biotherapeutics downgraded by UBS with a new price target

      UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00

      5/16/25 8:01:50 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Truist

      Truist downgraded Iovance Biotherapeutics from Buy to Hold

      5/12/25 8:21:43 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Citizens JMP

      Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform

      5/9/25 8:42:44 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    $IOVA
    $TRAW
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Kirby Daniel Gordon bought $55,200 worth of shares (30,000 units at $1.84) (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      6/6/25 4:05:31 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Regulatory Officer Puri Raj K. bought $9,743 worth of shares (5,600 units at $1.74), increasing direct ownership by 3% to 206,852 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      5/27/25 4:06:43 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Interim CEO & General Counsel Vogt Frederick G bought $42,250 worth of shares (25,000 units at $1.69), increasing direct ownership by 7% to 374,646 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      5/16/25 4:05:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    $IOVA
    $TRAW
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

      For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

      2/16/24 3:48:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    $IOVA
    $TRAW
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Clarke Trafford

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      6/23/25 5:59:03 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Stover Jack E

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      6/23/25 5:54:01 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shoemaker Mary Teresa

      4 - Traws Pharma, Inc. (0001130598) (Issuer)

      6/23/25 5:52:01 PM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IKNA
    $IOVA
    $TRAW
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

      Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue discussions on path forward for accelerated approval of TXM for bird flu Phase 2 study protocol submitted to HREC to evaluate ratutrelvir in newly diagnosed COVID patients, with extensions to measure disease rebound and development of Long COVID NEWTOWN, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to

      6/30/25 6:30:00 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on June 20, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 312,660 shares of Iovance's common stock to 58 new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 2

      6/23/25 4:05:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Present at Upcoming Conference

      SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at https://ir.iovance.com/news-events/events-presentations. About Iovance Biotherapeutics, Inc.  Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and deliver

      6/10/25 8:45:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    $IOVA
    $TRAW
    SEC Filings

    See more
    • Traws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Traws Pharma, Inc. (0001130598) (Filer)

      6/30/25 6:31:41 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Ikena Oncology Inc.

      SCHEDULE 13D/A - Ikena Oncology, Inc. (0001835579) (Subject)

      6/18/25 8:23:09 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13D filed by Ikena Oncology Inc.

      SCHEDULE 13D - Ikena Oncology, Inc. (0001835579) (Subject)

      6/16/25 12:21:15 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    $IOVA
    $TRAW
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ikena Oncology Inc.

      SC 13G - Ikena Oncology, Inc. (0001835579) (Subject)

      11/14/24 5:05:17 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      11/14/24 4:50:30 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ikena Oncology Inc.

      SC 13G/A - Ikena Oncology, Inc. (0001835579) (Subject)

      11/13/24 4:05:14 PM ET
      $IKNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IKNA
    $IOVA
    $TRAW
    Leadership Updates

    Live Leadership Updates

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

      SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today. "I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team," stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance. "Dan has been instrumental in building and leading cell therapy comm

      2/10/25 7:00:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors

      Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of Service NEWTOWN, Pa., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer, today announced the appointment of Luba Greenwood as Director. In addition, Director James J. Marino is stepping down after nearly ten years of dedicated service, including four years as Chairman, due to other professional co

      9/20/24 7:30:00 AM ET
      $TRAW
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IKNA
    $IOVA
    $TRAW
    Financials

    Live finance-specific insights

    See more
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

      SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming

      2/18/25 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

      Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lym

      11/7/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care